Clinical Observation for the Therapeutic Effect of mNGF on Cognitive Decline in Cerebral Small Vessel Disease
Status:
Recruiting
Trial end date:
2021-02-28
Target enrollment:
Participant gender:
Summary
This study was a multicenter, prospective, randomized controlled trial. In this study, 510
patients with cognitive impairment of cerebral small vessel disease who met the inclusion
criteria are randomly included in multiple centers and randomized into two groups (standard
treatment group and mouse nerve growth factor addition treatment group). The standard
treatment group is treated with conventional drugs and cholinesterase inhibitors. In addition
to the above treatment, the mouse nerve growth factor addition treatment group is
administered with nerve growth factor 20 μg (9000 U)/vial for 14 consecutive days,
intramuscularly once a day. Systematic clinical evaluation of patient cognitive function is
performed at baseline, 14-day, and 3-month follow-up, and imaging (MR) is also evaluated
twice at baseline, 14-day, and 3-month follow-up. At last observe the clinical effect of
mouse nerve growth factor on cognitive impairment of cerebral small vessel disease.
Phase:
Phase 4
Details
Lead Sponsor:
Zhujiang Hospital
Collaborators:
Dongguan People's Hospital First Affiliated Hospital of Jinan University First Affiliated Hospital of Shantou University Medical College First Affiliated Hospital, Sun Yat-Sen University Guangdong 999 Brain Hospital Houjie Hospital of Dongguan City Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University The First Affiliated Hospital of Guangdong Pharmaceutical University Wuhan University